智通财经APP获悉，周二，礼来(LLY.US)股价盘前走低，截至发稿，该股跌超1.5%，报1042.5美元。消息面上，礼来主要竞争对手诺和诺德(NVO.US)宣布，将下调旗下多款GLP-1类药物在美国的官方标价。
诺和诺德表示，自2027年1月1日起，公司将下调Wegovy、Ozempic和Rybelsus在美国市场的批发采购价。调整后，Wegovy和Ozempic的标价将较当前水平下调约35%至50%，相关调整同时适用于注射剂型和口服剂型。
具体来看，此次定价改革将把Wegovy注射剂和口服版本，以及Ozempic注射剂和Rybelsus口服药的月度标价统一降至675美元。目前，在利润丰厚的抗肥胖药物市场中，诺和诺德的市场表现仍落后于礼来。
诺和诺德在声明中表示，此次降价适用于上述药物的所有剂量，体现了公司在美国医疗体系不断演变的背景下，提升患者以及公共和私人支付方用药可负担性的承诺。
公司还指出，价格下调预计将尤其利好自付费用与官方标价挂钩的患者。不过，诺和诺德强调，此次调整不会影响其直面消费者的自费定价体系。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.